Targeting m⁶A Modifications Regulating Ferroptosis Offers Novel Therapy in Diseases

Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, emerged as a critical process in the pathogenesis of various diseases, including neurological, cardiovascular, hepatic, pulmonary, and renal disorders. Simultaneously, N6-methyladenosine (m⁶A), the most abundant reversible RNA modification in eukaryotes, plays a pivotal role in gene regulation by modulating RNA stability, translation, and degradation. Evidence increasingly links m⁶A modifications to the transcriptional and post-transcriptional regulation of ferroptosis, highlighting their importance in disease mechanisms. This review explores the molecular mechanisms underpinning m⁶A modifications and ferroptosis, detailing their interactions in disease progression. Additionally, it evaluates the therapeutic promise of targeting m⁶A regulators to modulate ferroptosis, offering novel approaches for managing diseases with diverse etiologies. By clarifying the role of m⁶A in ferroptosis, this review underscores the promise of m⁶A-focused therapeutic strategies in advancing treatment for diseases where ferroptosis plays a key pathological role.